NSNora Sipeki

Nora Sipeki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nora Sipeki has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct Thrombin Generation Patterns in Adult and Pediatric Inflammatory Bowel Disease Related to Inflammation and Disease Activity

    by Vivien Stercel, Rita Orbán-Kálmándi, Linda Lóczi, Dóra Bomberák, Rebeka Hodossy-Takács, Attila Ádám Szabó, Miklós Fagyas, Orsolya Kadenczki, Éva Nemes, Nóra Sipeki, et al.

    Background: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is associated with an increased risk of thrombosis. Although thrombin generation (TG) is a sensitive global measure of coagulation, age-related differences in hypercoagulability between adult and pediatric IBD remain poorly characterized.,Methods: Plasma samples from 193 adults (43 CD, 26 UC, 124 controls) and 121 children (27 CD, 29 UC, 65 controls) were analyzed using calibrated automated thrombography. TG parameters (lag time, endogenous thrombin potential [ETP], peak thrombin, and time to peak) were evaluated together with routine laboratory and inflammatory parameters, ACE/ACE2 activity, and clinical disease activity indices.,Results: Adult IBD patients exhibited significantly increased ETP and peak thrombin compared with healthy controls (ETP, median [IQR]: CD 1945 [1649–2223], UC 2050 [1738–2281], controls 1622 [1287–1840] nMmin; p<0.001), indicating persistent hypercoagulability. In contrast, pediatric patients showed no significant differences from controls, although children with active CD had significantly higher ETP and peak thrombin than those in remission. In both age groups, TG parameters correlated positively with inflammatory markers and disease activity, with more extensive associations observed in adults. A novel inverse correlation between ACE2 activity and peak thrombin was identified in adult patients,Conclusions: Adult and pediatric IBD exhibit distinct thrombin generation phenotypes. Adults demonstrate persistent hypercoagulability, whereas coagulation activation in children appears to be primarily associated with active inflammatory disease. The results suggest that thrombin generation testing may serve as a useful adjunct for age-specific assessment of thrombotic risk related to disease activity.

  • Open Access

    Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)

    by Ida Schregel, Maria Papp, Nora Sipeki, Patricia J. Kovats, Richard Taubert, Bastian Engel, Alejandro Campos‐Murguia, George N. Dalekos, Nikolaos Gatselis, Kalliopi Zachou, et al.

    Background and Aims: The European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) launched the prospective, multicentre, quality‐controlled R‐LIVER registry on rare liver diseases. The aim of this study was to assess the presentation and outcome of autoimmune hepatitis (AIH) after 1 year of treatment.Methods: Data were prospectively collected at the time of diagnosis and after 6 and 12 months follow‐up. Complete biochemical response (CBR) was defined as normalization of alanine aminotransferase (ALT) and immunoglobulin G (IgG) serum levels.Results: A total of 231 patients from six European centres were included in the analysis. After 6 months of treatment 50% (106/212), and after 12 months 63% (131/210) of patients reached CBR with only 27% (56/211) achieving a steroid‐free CBR within the first year.Overall, 16 different treatment regimens were administered. Change of treatment, mostly due to intolerance, occurred in 30.4% within the first 6 months. In multivariate analysis, younger age at diagnosis (odds ratio [OR] = 1.03 [95% confidence interval (CI) 1.01–1.05]; p = .007), severe fibrosis (OR .38 [95% .16–.89], p = .026) and change of treatment within the first 6 months (OR .40 [95% CI .2–.86]; p = .018) were associated with a lesser chance of ALT normalization at 12 months follow‐up.Conclusion: The landscape of AIH treatment in Europe is highly heterogeneous, even between expert centres. The results from this first European multicentre prospective registry reveal several unmet needs, highlighted by the overall low rates of CBR and the frequent failure to withdraw corticosteroids.


  • Open Access

    Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality

    by David Tornai, Zsuzsanna Vitalis, Alexa Jonas, Tamas Janka, Ildiko Foldi, Tamas Tornai, Nora Sipeki, Aniko Csillag, Boglarka Balogh, Andrea Sumegi, et al.


  • Open Access

    Anti-neutrophil cytoplasmic antibody testing by indirect immunofluorescence: Computer-aided versus conventional microscopic evaluation of routine diagnostic samples from patients with vasculitis or other inflammatory diseases

    by Gábor Nagy, István Csípő, Tünde Tarr, Gabriella Szűcs, Antónia Szántó, Tamás Bubán, Nóra Sipeki, Zoltán Szekanecz, Mária Papp, János Kappelmayer, et al.


  • Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months

    by Simon Pape, Tom J.G. Gevers, Jan Maarten Vrolijk, Bart van Hoek, Gerd Bouma, Carin M.J. van Nieuwkerk, Richard Taubert, Elmar Jaeckel, Michael P. Manns, Maria Papp, et al.


  • Open Access

    Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn’s Disease

    by Claudia Deutschmann, Mandy Sowa, Jayaseelan Murugaiyan, Uwe Roesler, Nadja Röber, Karsten Conrad, Martin W Laass, Dimitrios Bogdanos, Nora Sipeki, Maria Papp, et al.

    There is an increasing incidence of inflammatory bowel disease [IBD]. Autoimmune responses are involved in the pathophysiology of IBD, but their underlying pathways and target antigens have not yet been fully elucidated. Autoantigenic targets in IBD were identified after separation of whole cell proteins isolated from neutrophils using two-dimensional electrophoresis and matrix assisted laser desorption ionization – time of flight mass spectrometry-based protein identification of the spots that displayed Western blotting signals with anti-neutrophil cytoplasmic antibody-positive sera. The prevalence of IgG, IgA and secretory IgA [sIgA] to chitinase 3-like protein 1 [CHI3L1] was analysed by enzyme-linked immunosorbent assays using recombinant CHI3L1 in 110 patients with Crohn’s disease [CD], 95 with ulcerative colitis [UC], 126 with coeliac disease [CeD] and 86 healthy controls [HCs]. The 18-glycosylhydrolase family member CHI3L1 was identified as a neutrophil autoantigenic target. CD patients displayed significantly higher levels of IgG to CHI3L1 than patients with UC and CeD (p < 0.0001, respectively). IgA and sIgA to CHI3L1 was significantly higher in CD than in UC, CeD and HCs [p < 0.0001, respectively]. IgA and sIgA to CHI3L1 demonstrated the highest prevalence in CD [25.5%, 28/110; and 41.8%%, 46/110] compared to HCs [2.3%, 2/86; and 4.7%%, 4/86; p = 0.0015 and p < 0.0001] and are associated with a more complicated progression of CD. CHI3L1 is a novel neutrophil autoantigenic target in CD. IgA and sIgA to CHI3L1 may serve as novel markers for CD and may facilitate the serological diagnosis of IBD.


  • Open Access

    Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients

    by Gyorgy Kovacs, Nora Sipeki, Boglarka Suga, Tamas Tornai, Kai Fechner, Gary L Norman, Zakera Shums, Peter Antal-Szalmas, Maria Papp

    To determine the prognostic potential of classic and novel serologic antibodies regarding unfavorable disease course in a prospective ulcerative colitis (UC) patient cohort, since few and conflicting data are available in the literature regarding this matter. 187 consecutive patients were studied prospectively (median follow-up: 135 months) from a single referral IBD center in Hungary. Sera were tested for different IgA/IgG type autoantibodies (anti-neutrophil cytoplasmic [ANCA], anti-DNA-bound-lactoferrin [anti-LFS], anti-goblet cell [anti-GAB] and anti-pancreatic [PAB: anti-CUZD1 and anti-GP2)]) by indirect immunofluorescence technique and for anti-microbial (anti-Saccharomyces cerevisiae [ASCA] IgG/IgA and anti-OMP Plus™ IgA) antibodies by enzyme-linked immunosorbent assays. A total of 73.6%, 62.4% and 11.2% of UC patients were positive for IgA/IgG type of atypical perinuclear-ANCA, anti-LFS and anti-GAB, respectively. Occurrences of PABs were 9.6%, while ASCA IgA/IgG and anti-OMP IgA were 17.6% and 19.8%, respectively. Antibody status was stable over time. IgA type PABs were more prevalent in patients with primary sclerosing cholangitis (37.5% vs. 4.7% for anti-CUZD1 and 12.5% vs. 0% for anti-GP2, p.001 for both). IgA type ASCA and anti-CUZD1 antibodies were associated with higher risk of requirement for long-term immunosuppressant therapy in Kaplan-Meier analysis (pLogRank .01 for both). However, in multivariate Cox-regression analysis only ASCA IgA (HR: 2.74, 95%CI: 1.46–5.14, p.01) remained independent predictor. UC-related hospitalization due to disease activity was only associated with multiple antibody positivity (for 3 or more; HR 2.03 [95% CI: 1.16–3.56]; p = 0.013). None of the individual antibodies or their combination was associated with the risk of development of extensive disease or colectomy. Even with low prevalence rates, present study gives further evidence to the role of certain antibodies as markers for distinct phenotype and disease outcome in UC. Considering the result of the multivariate analysis the novel antibodies investigated do not seem to be associated with poor clinical outcome in UC, only a classic antibody, IgA subtype ASCA remained an independent predictor of long-term immunosuppressive therapy.


  • Open Access

    Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis

    by Tamas Tornai, David Tornai, Nora Sipeki, Istvan Tornai, Rayan Alsulaimani, Kai Fechner, Dirk Roggenbuck, Gary L. Norman, Gabor Veres, Gabriella Par, et al.

    Glycoprotein 2[GP2] is a specific target of pancreatic autoantibodies[PAbs] in Crohn’s disease(CD) and is involved in gut innate immunity processes. Our aim was to evaluate the prevalence and prognostic potential of PAbs in primary sclerosing cholangitis(PSC). Sixty-five PSC patients were tested for PAbs by indirect immunofluorescence and compared with healthy (n = 100) and chronic liver disease controls(CLD, n = 488). Additionally, a panel of anti-microbial antibodies and secretory (s)IgA levels were measured, as markers of bacterial translocation and immune dysregulation. PAbs were more frequent in PSC(46.2%) compared to controls(healthy:0% and CLD:4.5%), [P < 0.001, for each]. Occurrence of anti-GP2 antibody was 30.8% (20/65) and was exclusively of IgA isotype. Anti-GP2 IgA positive patients had higher sIgA levels (P = 0.021). With flow-cytometry, 68.4% (13/19) of anti-GP2 IgA antibodies were bound with secretory component, suggesting an active retro-transportation of anti-GP2 from the gut lumen to the mucosa. Anti-GP2 IgA was associated with shorter transplant-free survival [PLogRank < 0.01] during the prospective follow-up (median, IQR: 87 [9–99] months) and remained an independent predictor after adjusting for Mayo risk score(HR: 4.69 [1.05–21.04], P = 0.043). These results highlight the significance of gut-liver interactions in PSC. Anti-GP2 IgA might be a valuable tool for risk stratification in PSC and considered as a potential therapeutic target.


  • Lectin‐complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections

    by Ildiko Foldi, Tamas Tornai, David Tornai, Nora Sipeki, Zsuzsanna Vitalis, Istvan Tornai, Tamas Dinya, Peter Antal‐Szalmas, Maria Papp

    Background & Aims: Lectin pathway molecules of the complement system are synthesized by hepatocytes and have pivotal role in innate host defence against infectious organisms. Ficolins (FCNs) act as soluble pattern recognition molecules, while mannan‐binding lectin serine proteases(MASPs) do as effector molecules in elimination of pathogens. We aimed to study the significance of low level of these molecules in the development of cirrhosis‐associated bacterial infections, which has not been elucidated so far.Methods: Sera of 266 stable outpatients with cirrhosis and 160 healthy subjects were assayed for a panel of lectin molecules (FCN‐2, FCN‐3 and MASP‐2) by ELISA. In cirrhosis, a 5‐year follow‐up observational study was conducted to assess a possible association between lectin levels and development of clinically significant bacterial infections(CSI).Results: FCN‐2, FCN‐3 and MASP‐2 levels were significantly lower in cirrhosis compared to healthy subjects and decreased according to disease severity (P<.001 for all molecules). In Kaplan‐Meier analysis, development of CSI was associated with low level of FCN‐2 (pLogRank=0.047) and FCN‐3 (pLogRank=0.029), but not with MASP‐2 deficiency (pLogRank=0.306). Combined FCN deficiency was associated with increased risk of development of bacterial infections in a step‐wise manner. Patients with low level of both FCNs had higher cumulative probability of CSI (63.8%) compared to those with low level of one or normal FCN (52.7% and 45.7%, pLogRank=0.016). Neither FCN serum profile, nor MASP‐2 deficiency were associated with infection‐related mortality.Conclusions: Low level of FCNs associated with hepatic insufficiency might be considered as an additional constituent of cirrhosis‐associated immune dysfunction.


  • Macrophage activation marker, soluble CD163, is an independent predictor of short‐term mortality in patients with cirrhosis and bacterial infection

    by Tamas Tornai, Zsuzsanna Vitalis, Nora Sipeki, Tamas Dinya, David Tornai, Peter Antal‐Szalmas, Zsolt Karanyi, Istvan Tornai, Maria Papp

    Background & Aims: Innate immune system dysfunction is common in advanced cirrhosis, with a central role of the monocyte/macrophage system. Monocytes and macrophages express the scavenger receptor CD163, which is regulated by inflammatory mediators. Cleavage of the receptor leads to the formation of soluble (s)CD163 that represents an anti‐inflammatory response. We aimed to study the clinical importance of sCD163 in cirrhosis.Methods: Sera of 378 patients were assayed for sCD163 by ELISA [193 outpatients and 185 patients with acute decompensation (AD)]. A 5‐year follow‐up observational study was conducted to assess the possible association between sCD163 level and poor disease outcomes.Results: sCD163 level was associated with disease severity, but not with the presence of varices or prior variceal bleeding. In outpatients, sCD163 level did not predict the development of disease‐specific complications or the long‐term mortality. In patients with AD episode, sCD163 level was significantly higher compared to outpatients but only in the presence of bacterial infection (INF) (AD‐INF:4586, AD‐NON‐INF:3792 and outpatients: 3538 ng/ml, P < 0.015 and P = 0.001, respectively). sCD163 level gradually increased according to severity of infection. During bacterial infections, high sCD163 level (>7000 ng/ml) was associated with increased mortality rate (42% vs. 17%, P < 0.001) and was identified as an independent predictor of 28‐day mortality (hazard ratio:2.96, 95% confidence intervals:1.27–6.95) in multivariate Cox‐regression model comprising aetiology, co‐morbidity, model for end‐stage liver disease score and leucocyte count as covariates.Conclusions: High sCD163 level is useful to identify patients with high‐risk of death during an AD episode complicated by bacterial infection. This finding serves as an additional hint towards the significance of anti‐inflammatory response during bacterial infection.